Clinical Significance

CA242 is a sialylated glycosphingolipid antigen that is almost always expressed together with CA50, but the two are recognized by different monoclonal antibodies. It has been clinically used for the diagnosis of digestive tract malignant tumors, especially pancreatic cancer and colorectal cancer. Compared with CA19-9 and CA50, the new generation of CA242 has the sensitivity and specificity in pancreatic cancer, gallbladder cancer and digestive tract cancer. The sex is higher (CA50, CA19-9 are susceptible to liver function and cholestasis, and false positives often occur in benign obstructive jaundice and liver parenchymal lesions).